Kodiak Sciences Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Kodiak Sciences is a biopharmaceutical company developing therapies for retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Its lead product candidate, tarcocimab, is designed to extend the durability of anti-VEGF treatment through an antibody biopolymer conjugate platform.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| BORGESON JOHN A.Chief Financial Officer | Sell | $746K | 8,514at $87.67 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $684K | 7,623at $89.74 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $464K | 5,101at $90.98 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $274K | 2,985at $91.76 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $187K | 2,000at $93.71 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $185K | 2,000at $92.66 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $150K | 1,677at $89.20 | Oct 21, 2026 |
| BORGESON JOHN A.Chief Financial Officer | Sell | $9K | 100at $94.91 | Oct 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable KOD activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.